PTGS2 and urinary bladder carcinoma: Our findings might be viewed as an open promising opportunity for improvement of pharmacological bladder cancer management based on preventive strategies of COX-2 inhibition but should also be viewed as an alert concerning its potential deleterious application in patients with consistent bladder cancer stages.